晚期非小细胞肺癌靶向治疗新进展

被引：7

作者：

陈智伟

机构：

[1] 上海交通大学附属胸科医院上海市肺部肿瘤临床医学中心

来源：

实用临床医药杂志 | 2009年 / 13卷 / 07期

关键词：

靶向治疗; 非小细胞肺癌; 化学治疗;

D O I：

暂无

中图分类号：

R734.2 [肺肿瘤];

学科分类号：

100117 [系统生物医学];

摘要：

引用

页码：18 / 21+30 +30

页数：5

共 4 条

[1]

Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer [J].

Cufer, Tania ;

Vrdoljak, Eduard ;

Gaafar, Rabab ;

Erensoy, Inci ;

Pemberton, Kristine .

ANTI-CANCER DRUGS, 2006, 17 (04) :401-409

[2]

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) [J].

Thatcher, N ;

Chang, A ;

Parikh, P ;

Pereira, JR ;

Ciuleanu, T ;

von Pawel, J ;

Thongprasert, S ;

Tan, EH ;

Pemberton, K ;

Archer, V ;

Carroll, K .

LANCET, 2005, 366 (9496) :1527-1537

[3]

O-086a Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C)with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial — E4599.[J].A.B. Sandler;R. Gray;J. Brahmer;A. Dowlati;J.H. Schiller;M.C. Perry;D.H. Johnson.Lung Cancer.2005,

[4]

Revisions in the International System for Staging Lung Cancer [J].

Mountain, CF .

CHEST, 1997, 111 (06) :1710-1717

← 1 →